Investigating the genetic architecture of dementia with Lewy bodies : a two-stage genome-wide association study
(2018) In The Lancet Neurology 17(1). p.64-74- Abstract
Background Dementia with Lewy bodies is the second most common form of dementia in elderly people but has been overshadowed in the research field, partly because of similarities between dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. So far, to our knowledge, no large-scale genetic study of dementia with Lewy bodies has been done. To better understand the genetic basis of dementia with Lewy bodies, we have done a genome-wide association study with the aim of identifying genetic risk factors for this disorder. Methods In this two-stage genome-wide association study, we collected samples from white participants of European ancestry who had been diagnosed with dementia with Lewy bodies according to established... (More)
Background Dementia with Lewy bodies is the second most common form of dementia in elderly people but has been overshadowed in the research field, partly because of similarities between dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. So far, to our knowledge, no large-scale genetic study of dementia with Lewy bodies has been done. To better understand the genetic basis of dementia with Lewy bodies, we have done a genome-wide association study with the aim of identifying genetic risk factors for this disorder. Methods In this two-stage genome-wide association study, we collected samples from white participants of European ancestry who had been diagnosed with dementia with Lewy bodies according to established clinical or pathological criteria. In the discovery stage (with the case cohort recruited from 22 centres in ten countries and the controls derived from two publicly available database of Genotypes and Phenotypes studies [phs000404.v1.p1 and phs000982.v1.p1] in the USA), we performed genotyping and exploited the recently established Haplotype Reference Consortium panel as the basis for imputation. Pathological samples were ascertained following autopsy in each individual brain bank, whereas clinical samples were collected after participant examination. There was no specific timeframe for collection of samples. We did association analyses in all participants with dementia with Lewy bodies, and also only in participants with pathological diagnosis. In the replication stage, we performed genotyping of significant and suggestive results from the discovery stage. Lastly, we did a meta-analysis of both stages under a fixed-effects model and used logistic regression to test for association in each stage. Findings This study included 1743 patients with dementia with Lewy bodies (1324 with pathological diagnosis) and 4454 controls (1216 patients with dementia with Lewy bodies vs 3791 controls in the discovery stage; 527 vs 663 in the replication stage). Results confirm previously reported associations: APOE (rs429358; odds ratio [OR] 2·40, 95% CI 2·14–2·70; p=1·05 × 10−48), SNCA (rs7681440; OR 0·73, 0·66–0·81; p=6·39 × 10−10), an GBA (rs35749011; OR 2·55, 1·88–3·46; p=1·78 × 10−9). They also provide some evidence for a novel candidate locus, namely CNTN1 (rs7314908; OR 1·51, 1·27–1·79; p=2·32 × 10−6); further replication will be important. Additionally, we estimate the heritable component of dementia with Lewy bodies to be about 36%. Interpretation Despite the small sample size for a genome-wide association study, and acknowledging the potential biases from ascertaining samples from multiple locations, we present the most comprehensive and well powered genetic study in dementia with Lewy bodies so far. These data show that common genetic variability has a role in the disease. Funding The Alzheimer's Society and the Lewy Body Society.
(Less)
- author
- organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The Lancet Neurology
- volume
- 17
- issue
- 1
- pages
- 11 pages
- publisher
- Lancet Publishing Group
- external identifiers
-
- pmid:29263008
- scopus:85039561634
- ISSN
- 1474-4422
- DOI
- 10.1016/S1474-4422(17)30400-3
- language
- English
- LU publication?
- yes
- id
- 3db91543-ef1e-4af9-8603-3892a05ee40e
- date added to LUP
- 2018-01-22 11:51:27
- date last changed
- 2024-04-14 23:27:30
@article{3db91543-ef1e-4af9-8603-3892a05ee40e,
abstract = {{<p>Background Dementia with Lewy bodies is the second most common form of dementia in elderly people but has been overshadowed in the research field, partly because of similarities between dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. So far, to our knowledge, no large-scale genetic study of dementia with Lewy bodies has been done. To better understand the genetic basis of dementia with Lewy bodies, we have done a genome-wide association study with the aim of identifying genetic risk factors for this disorder. Methods In this two-stage genome-wide association study, we collected samples from white participants of European ancestry who had been diagnosed with dementia with Lewy bodies according to established clinical or pathological criteria. In the discovery stage (with the case cohort recruited from 22 centres in ten countries and the controls derived from two publicly available database of Genotypes and Phenotypes studies [phs000404.v1.p1 and phs000982.v1.p1] in the USA), we performed genotyping and exploited the recently established Haplotype Reference Consortium panel as the basis for imputation. Pathological samples were ascertained following autopsy in each individual brain bank, whereas clinical samples were collected after participant examination. There was no specific timeframe for collection of samples. We did association analyses in all participants with dementia with Lewy bodies, and also only in participants with pathological diagnosis. In the replication stage, we performed genotyping of significant and suggestive results from the discovery stage. Lastly, we did a meta-analysis of both stages under a fixed-effects model and used logistic regression to test for association in each stage. Findings This study included 1743 patients with dementia with Lewy bodies (1324 with pathological diagnosis) and 4454 controls (1216 patients with dementia with Lewy bodies vs 3791 controls in the discovery stage; 527 vs 663 in the replication stage). Results confirm previously reported associations: APOE (rs429358; odds ratio [OR] 2·40, 95% CI 2·14–2·70; p=1·05 × 10<sup>−48</sup>), SNCA (rs7681440; OR 0·73, 0·66–0·81; p=6·39 × 10<sup>−10</sup>), an GBA (rs35749011; OR 2·55, 1·88–3·46; p=1·78 × 10<sup>−9</sup>). They also provide some evidence for a novel candidate locus, namely CNTN1 (rs7314908; OR 1·51, 1·27–1·79; p=2·32 × 10<sup>−6</sup>); further replication will be important. Additionally, we estimate the heritable component of dementia with Lewy bodies to be about 36%. Interpretation Despite the small sample size for a genome-wide association study, and acknowledging the potential biases from ascertaining samples from multiple locations, we present the most comprehensive and well powered genetic study in dementia with Lewy bodies so far. These data show that common genetic variability has a role in the disease. Funding The Alzheimer's Society and the Lewy Body Society.</p>}},
author = {{Guerreiro, Rita and Ross, Owen A. and Kun-Rodrigues, Celia and Hernandez, Dena G. and Orme, Tatiana and Eicher, John D. and Shepherd, Claire E. and Parkkinen, Laura and Darwent, Lee and Heckman, Michael G. and Scholz, Sonja W. and Troncoso, Juan C. and Pletnikova, Olga and Ansorge, Olaf and Clarimon, Jordi and Lleo, Alberto and Morenas-Rodriguez, Estrella and Clark, Lorraine and Honig, Lawrence S. and Marder, Karen and Lemstra, Afina and Rogaeva, Ekaterina and St George-Hyslop, Peter and Londos, Elisabet and Zetterberg, Henrik and Barber, Imelda and Braae, Anne and Brown, Kristelle and Morgan, Kevin and Troakes, Claire and Al-Sarraj, Safa and Lashley, Tammaryn and Holton, Janice and Compta, Yaroslau and Van Deerlin, Vivianna and Serrano, Geidy E. and Beach, Thomas G. and Lesage, Suzanne and Galasko, Douglas and Masliah, Eliezer and Santana, Isabel and Pastor, Pau and Diez-Fairen, Monica and Aguilar, Miquel and Tienari, Pentti J. and Myllykangas, Liisa and Oinas, Minna and Revesz, Tamas and Lees, Andrew and Boeve, Brad F. and Petersen, Ronald C. and Ferman, Tanis J. and Escott-Price, Valentina and Graff-Radford, Neill and Cairns, Nigel J. and Morris, John C. and Pickering-Brown, Stuart and Mann, David and Halliday, Glenda M. and Hardy, John and Trojanowski, John Q. and Dickson, Dennis W. and Singleton, Andrew and Stone, David J. and Bras, Jose}},
issn = {{1474-4422}},
language = {{eng}},
number = {{1}},
pages = {{64--74}},
publisher = {{Lancet Publishing Group}},
series = {{The Lancet Neurology}},
title = {{Investigating the genetic architecture of dementia with Lewy bodies : a two-stage genome-wide association study}},
url = {{http://dx.doi.org/10.1016/S1474-4422(17)30400-3}},
doi = {{10.1016/S1474-4422(17)30400-3}},
volume = {{17}},
year = {{2018}},
}